Notice2023-19779
Findings of Research Misconduct
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
September 13, 2023
Issuing agencies
Health and Human Services Department
Abstract
Findings of research misconduct have been made against Andrew Dannenberg, M.D. (Respondent), who was a Professor of Medicine, Department of Medicine, Weill Cornell Medical College (WCMC). Respondent engaged in research misconduct in research supported by U.S. Public Health Service (PHS) funds, specifically National Cancer Institute (NCI), National Institutes of Health (NIH), grants P01 CA077839, P01 CA106451, R01 CA108773, R01 CA154481, T32 CA009685, R25 CA105012, and N01 CN43302, National Institute on Deafness and Other Communication Disorders (NIDCD), NIH, grant T32 DC000027, and National Center for Advancing Translational Sciences (NCATS), NIH, grant UL1 TR000457. The administrative actions, including supervision for a period of seven (7) years, were implemented beginning on August 14, 2023, and are detailed below.
Full Text
<html>
<head>
<title>Federal Register, Volume 88 Issue 176 (Wednesday, September 13, 2023)</title>
</head>
<body><pre>
[Federal Register Volume 88, Number 176 (Wednesday, September 13, 2023)]
[Notices]
[Pages 62803-62807]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2023-19779]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Office of the Secretary
Findings of Research Misconduct
AGENCY: Office of the Secretary, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: Findings of research misconduct have been made against Andrew
Dannenberg, M.D. (Respondent), who was a Professor of Medicine,
Department of Medicine, Weill Cornell Medical College (WCMC).
Respondent engaged in research misconduct in research supported by U.S.
Public Health Service (PHS) funds, specifically National Cancer
Institute (NCI), National Institutes of Health (NIH), grants P01
CA077839, P01 CA106451, R01 CA108773, R01 CA154481, T32 CA009685, R25
CA105012, and N01 CN43302, National Institute on Deafness and Other
Communication Disorders (NIDCD), NIH, grant T32 DC000027, and National
Center for Advancing Translational Sciences (NCATS), NIH, grant UL1
TR000457. The administrative actions, including supervision for a
period of seven (7) years, were implemented beginning on August 14,
2023, and are detailed below.
FOR FURTHER INFORMATION CONTACT: Sheila Garrity, JD, MPH, MBA,
Director, Office of Research Integrity, 1101 Wootton Parkway, Suite
240, Rockville, MD 20852, (240) 453-8200.
SUPPLEMENTARY INFORMATION: Notice is hereby given that the Office of
Research Integrity (ORI) has taken final action in the following case:
Andrew Dannenberg, M.D., Weill Cornell Medical College (WCMC):
Based on the report of an investigation conducted by WCMC and
additional analysis conducted by ORI in its oversight review, ORI found
that Andrew Dannenberg, former Professor of Medicine, Department of
Medicine, WCMC, engaged in research misconduct in research supported by
PHS funds, specifically NCI, NIH, grants P01 CA077839, P01 CA106451,
R01 CA108773, R01 CA154481, T32 CA009685, R25 CA105012, and N01
CN43302, NIDCD, NIH, grant T32 DC000027, and NCATS, NIH, grant UL1
TR000457.
ORI found that Respondent engaged in research misconduct by
recklessly reporting falsified and/or fabricated data in the following
twelve (12) published papers:
<bullet> Increased levels of COX-2 and prostaglandin E2 contribute
to elevated aromatase expression in inflamed breast tissue of obese
women. Cancer Discov. 2012 Apr;2(4):356-65. doi: 10.1158/2159-8290.CD-
11-0241 (hereafter referred to as ``Cancer Discov. 2012''). Retraction
in: Cancer Discov. 2021 May;11(5):1306. doi: 10.1158/2159-8290.CD-21-
0224.
<bullet> EP2 and EP4 receptors regulate aromatase expression in
human
[[Page 62804]]
adipocytes and breast cancer cells. Evidence of a BRCA1 and p300
exchange. J Biol Chem. 2008 Feb 8;283(6):3433-44. doi: 10.1074/
jbc.M705409200 (hereafter referred to as ``J Biol Chem. 2008'').
Retraction in: J Biol Chem. 2020 Jan 3; 295(1):295. doi: 10.1074/
jbc.W119.012140.
<bullet> HDAC6 modulates Hsp90 chaperone activity and regulates
activation of aryl hydrocarbon receptor signaling. J Biol Chem. 2009
Mar 20; 284(12):7436-45. doi: 10.1074/jbc.M808999200 (hereafter
referred to as ``J Biol Chem. 2009''). Retraction in: J Biol Chem. 2020
Jan 3; 295(1):297. doi: 10.1074/jbc.W119.012142.
<bullet> p53 protein regulates Hsp90 ATPase activity and thereby
Wnt signaling by modulating Aha1 expression. J Biol Chem. 2014 Mar
7;289(10):6513-25. doi: 10.1074/jbc.M113.532523 (hereafter referred to
as ``J Biol Chem. 2014''). Retraction in: J Biol Chem. 2020 Jan 3;
295(1):289. doi: 10.1074/jbc.W119.012134.
<bullet> Hsp90 and PKM2 drive the expression of aromatase in Li-
Fraumeni syndrome breast adipose stromal cells. J Biol Chem. 2016 Jul
29;291(31):16011-23. doi: 10.1074/jbc.M115.698902 (hereafter referred
to as ``J Biol Chem. 2016''). Retraction in: J Biol Chem. 2020 Jan 3;
295(1):290. doi: 10.1074/jbc.W119.012135.
<bullet> Heat shock protein 90 inhibitors suppress aryl hydrocarbon
receptor-mediated activation of CYP1A1 and CYP1B1 transcription and DNA
adduct formation. Cancer Prev Res (Phila). 2008 Nov;1(6):485-93. doi:
10.1158/1940-6207.CAPR-08-0149 (hereafter referred to as ``Cancer Prev
Res. 2008''). Retraction in: Cancer Prev Res (Phila). 2022 Jun
2;15(6):415. doi: 10.1158/1940-6207.CAPR-22-0200.
<bullet> Obesity is associated with inflammation and elevated
aromatase expression in the mouse mammary gland. Cancer Prev Res
(Phila). 2011 Mar;4(3):329-46. doi: 10.1158/1940-6207.CAPR-10-0381
(hereafter referred to as ``Cancer Prev Res. 2011''). Retraction in:
Cancer Prev Res (Phila). 2022 Jun 2; 15(6):413. doi: 10.1158/1940-
6207.CAPR-22-0202.
<bullet> Carnosol, a constituent of Zyflamend, inhibits aryl
hydrocarbon receptor-mediated activation of CYP1A1 and CYP1B1
transcription and mutagenesis. Cancer Prev Res (Phila). 2012
Apr;5(4):593-602. doi: 10.1158/1940-6207.CAPR-12-0002 (hereafter
referred to as ``Cancer Prev Res. 2012a''). Retraction in: Cancer Prev
Res (Phila). 2022 Jun 2;15(6):412. doi: 10.1158/1940-6207.CAPR-22-0203.
<bullet> Pioglitazone, a PPAR[gamma] agonist, suppresses CYP19
transcription: evidence for involvement of 15-hydroxyprostaglandin
dehydrogenase and BRCA1. Cancer Prev Res (Phila). 2012 Oct;5(10):1183-
94. doi: 10.1158/1940-6207.CAPR-12-0201 (hereafter referred to as
``Cancer Prev Res. 2012b''). Retraction in: Cancer Prev Res (Phila).
2022 Jun 2;15(6):411. doi: 10.1158/1940-6207.CAPR-22-0204.
<bullet> Caloric restriction reverses obesity-induced mammary gland
inflammation in mice. Cancer Prev Res (Phila). 2013 Apr;6(4):282-9.
doi: 10.1158/1940-6207.CAPR-12-0467 (hereafter referred to as ``Cancer
Prev Res. 2013''). Retraction in: Cancer Prev Res (Phila). 2022 Jun 2;
15(6):410. doi: 10.1158/1940-6207.CAPR-22-0205.
<bullet> p53 modulates Hsp90 ATPase activity and regulates aryl
hydrocarbon receptor signaling. Cancer Prev Res (Phila). 2014
Jun;7(6):596-606. doi: 10.1158/1940-6207.CAPR-14-0051 (hereafter
referred to as ``Cancer Prev Res. 2014''). Retraction in: Cancer Prev
Res (Phila). 2022 Jun 2;15(6):408. doi: 10.1158/1940-6207.CAPR-22-0207.
<bullet> Id1 deficiency protects against tumor formation in
Apc(Min/+) mice but not in a mouse model of colitis-associated colon
cancer. Cancer Prev Res (Phila). 2015 Apr;8(4):303-11. doi: 10.1158/
1940-6207.CAPR-14-0411 (hereafter referred to as ``Cancer Prev Res.
2015''). Retraction in: Cancer Prev Res (Phila). 2022 Jun 2;15(6):407.
doi: 10.1158/1940-6207.CAPR-22-0208.
Respondent recklessly reported falsified and/or fabricated Western
blot image data that were reused, with or without manipulation to
conceal their similarities, and falsely relabeled as data representing
different experiments or proteins in sixty (60) figure panels included
in twelve (12) published papers. In the absence of reliable image and
numerical data, the figures, statistical analyses, and related text
also are false.
Specifically, Respondent reported Western blot images that were
reused from the same source and falsely relabeled to represent
different proteins and/or experimental results in:
<bullet> Cancer Discov. 2012:
--Figure 2B, [beta]-Actin panel, representing [beta]-Actin expression
in inflamed breast tissue with different levels of inflammation:
[ssquf] All lanes are duplicated by reusing a same source band with
manipulation
--Figure 4C, representing the expression of progesterone receptor (PR)
and [beta]-Actin in inflamed breast tissue with different levels of
inflammation:
[ssquf] PR panel: Lanes 1, 2, and 14-16 are duplicated by reusing a
same source band with manipulation; lanes 3, 6-9, 13, and 17 are
duplicated by reusing a same source band with manipulation
[ssquf] [beta]-Actin panel: All lanes are duplicated by reusing a
same source band with manipulation
--Figure 5H, [beta]-Actin panel, representing [beta]-Actin expression
in macrophages with different treatments:
[ssquf] Lane 2 and lane 4 are identical
<bullet> J Biol Chem. 2008:
--Figure 2B, lanes 1-3, Aromatase panel, representing aromatase
expression in adipocytes treated with PGE1 alcohol, and Figure 2E,
lanes 2-4, Aromatase panel, representing aromatase expression in
adipocytes treated with PGE<INF>2</INF> with or without ONO, are
duplicated by reusing the same source images with manipulation
--Figure 3B, 18S rRNA panel, representing 18S rRNA expression in
adipocytes with different treatments:
[ssquf] Lanes 2 and 6 are identical
[ssquf] Lanes 3 and 7 are identical
--Figure 5A, 18S rRNA panel, representing 18S rRNA expression in
adipocytes treated with different doses of PGE<INF>2</INF>:
[ssquf] Lanes 1 and 5 are identical
[ssquf] Lanes 2 and 6 are identical
--Figure 5B, [beta]-actin panel, representing [beta]-actin expression
in adipocytes treated with different doses of PGE<INF>2</INF>:
[ssquf] Lanes 1, 3, and 4 are identical
--Figure 6D, BRCA1 and Aromatase panels, representing expression of
both BRCA1 and aromatase in SKBR3 cells treated with different doses of
PGE1 alcohol:
[ssquf] Lanes 3-4, BRCA1 panel and lanes 1-2, Aromatase panel are
duplicated by reusing the same source images with manipulation
--Figure 5A, BRCA1 panel, representing BRCA1 expression in adipocytes
treated with different doses of PGE<INF>2</INF>:
[ssquf] Lanes 3-6 are falsified and/or fabricated
--Figure 5C, 18S rRNA panel, representing 18S rRNA expression in
adipocytes treated with different doses of butaprost:
[ssquf] Entire 18S rRNA panel is falsified and/or fabricated
--Figure 5E:
[ssquf] Lane 4, BRCA1 panel and lane 1, 18S rRNA panel are
identical
--Figures 6C, 6D, 6E, and 6F:
[ssquf] Images used in the following figures are duplicated by
reusing the same source images with manipulation:
[rtarr8] Figure 6C, lane 1, BRCA1 panel, representing BRCA1
expression in control sample without treatment of butaprost
[[Page 62805]]
[rtarr8] Figure 6C, lane 3, Aromatase panel, representing aromatase
expression with 0.25 [mu]M butaprost treatment
[rtarr8] Figure 6D, lane 1, BRCA1 panel, representing BRCA1
expression in control sample without treatment of PGE1 alcohol
[rtarr8] Figure 6F, lane 1, BRCA1 panel, representing BRCA1
expression in control sample without treatment of PGE<INF>2</INF> and
ONO
[ssquf] Images used in the following figures are duplicated by
reusing the same source images with manipulation:
[rtarr8] Figure 6C, lane 2, BRCA1 panel, representing BRCA1
expression in sample treated with 0.10 [mu]M butaprost
[rtarr8] Figure 6D, lane 3, Aromatase panel, representing aromatase
expression in sample treated with 0.25 [mu]M PGE1 alcohol
[ssquf] Images used in the following figures are duplicated by
reusing the same source images with manipulation:
[rtarr8] Figure 6C, lane 3, BRCA1 panel, representing BRCA1
expression in sample treated with 0.25 [mu]M butaprost
[rtarr8]Figure 6D, lane 3, BRCA1 panel, representing BRCA1
expression in sample treated with 0.25 [mu]M PGE1 alcohol
[rtarr8]Figure 6D, lane 2, Aromatase panel, representing aromatase
expression in sample treated with 0.10 [mu]M PGE1 alcohol
[ssquf] Images used in the following figures are duplicated by
reusing the same source images with manipulation:
[rtarr8]Figure 6C, lane 4, BRCA1 panel, representing BRCA1
expression in sample treated with 0.50 [mu]M butaprost
[rtarr8]Figure 6C, lane 1, Aromatase panel, representing aromatase
expression in control sample without treatment of butaprost
[rtarr8]Figure 6D, lane 1, Aromatase panel, representing aromatase
expression in control sample without treatment of PGE1 alcohol
[rtarr8]Figure 6E, lane 2, BRCA1 panel, representing BRCA1
expression in sample treated with PGE<INF>2</INF> without AH6809
[ssquf] Images used in the following figures are duplicated by
reusing the same source images with manipulation:
[rtarr8]Figure 6C, lane 2, Aromatase panel, representing aromatase
expression in sample treated with 0.10 [mu]M butaprost
[rtarr8]Figure 6E, lane 3, BRCA1 panel, representing BRCA1
expression in sample treated with PGE<INF>2</INF> and 25 [mu]M AH6809
[rtarr8]Figure 6F, lane 2, BRCA1 panel, representing BRCA1
expression in sample treated with PGE<INF>2</INF> but without ONO
[ssquf] Images used in the following figures are duplicated by
reusing the same source images with manipulation:
[rtarr8]Figure 6C, lane 4, Aromatase panel, representing aromatase
expression in sample treated with 0.50 [mu]M butaprost
[rtarr8]Figure 6D, lane 2, BRCA1 panel, representing BRCA1
expression in sample treated with 0.10 [mu]M PGE1 alcohol
[rtarr8]Figure 6E, lane 4, BRCA1 panel, representing BRCA1
expression in sample treated with PGE<INF>2</INF> and 50 [mu]M AH6809
[rtarr8]Figure 6F, lane 3, BRCA1 panel, representing BRCA1
expression in sample treated with PGE<INF>2</INF> and 0.10 [mu]M ONO
[ssquf] Images used in the following figures are duplicated by
reusing the same source images with manipulation:
[rtarr8]Figure 6D, 18S rRNA panel, representing 18S rRNA expression
in samples treated with different doses of PGE1 alcohol
[rtarr8]Figure 6F, 18S rRNA panel, representing 18S rRNA expression
in samples treated with different doses of PGE<INF>2</INF> and ONO
<bullet> J Biol Chem. 2009:
--Figures 2A and 2B, [beta]-actin panels, representing [beta]-actin
expression in KYSE450 cells and MSK-Leuk1 cells, respectively:
[ssquf] The two panels are identical
--Figure 3B, representing protein expression at two different time
points:
[ssquf] Column 4, 1-hour panel, and column 2, 3-hour panel, are
duplicated by reusing the same source images with resizing
--Figure 6H, representing expression of different proteins with
different treatments:
[ssquf] Column 1, Control group and column 3, Control siRNA group
are identical
--Figure 6I, representing expression of different proteins with
different treatments:
[ssquf] Lanes 2 and 5, column 1 are identical
[ssquf] Lane 3, column 1 and lane 5, column 2 are identical
--Figure 8G, Input panel, representing input protein expression in A549
cells with different treatments:
[ssquf] Lanes 2 and 3 are identical
--Figure 9B, Input panel, representing input protein expression in
different samples:
[ssquf] Lanes 2 and 3 are identical
--Figures 8E and 9D:
[ssquf] Images used in the following figures are duplicated by
reusing a same source band with resizing:
[rtarr8]Figure 8E, lane 2, AhR panel, representing AhR expression
in sample treated with B[a]P
[rtarr8]Figure 9D, lane 3, [beta]-actin panel, representing [beta]-
actin expression in K/R sample treated with TS
--Figure 9D, [beta]-actin panel, representing [beta]-actin expression
under different experimental conditions:
[ssquf] Lane 1 is falsified and/or fabricated
--Figure 9C, Input panel, representing input protein expression in K/A
sample:
[ssquf] Lane 5 is falsified and/or fabricated
--Figure S1A, p23 panel, representing p23 expression in MSK-Leuk1 cells
and A549 cells:
[ssquf] Lanes 1 and 2 are identical
--Figure S1C, XAP-2 panel, representing XAP-2 expression in control and
sample treated with HDAC6 KD:
[ssquf] Lanes 1 and 2 are identical
--Figure S1B, representing expression of different proteins in MSK-
Leuk1 cells with different treatments:
[ssquf] Lanes 3 and 4, Hsp90 panel are identical
[ssquf] Lanes 1 and 2, AhR panel are identical
[ssquf] Lanes 1 and 2, [beta]-actin panel are identical
[ssquf] Lanes 3 and 4, [beta]-actin panel are identical
--Figure S1E, representing expression of different proteins in MSK-
Leuk1 cells with different treatments:
[ssquf] Lane 1, Hsp90 panel, and lanes 1 and 2, HDAC6 panel, are
identical
[ssquf] Lane 3, Hsp90 panel, and lane 3, XAP-2 panel, are identical
--Figure S2, representing expression of different proteins in MSK-Leuk1
cells with different treatments:
[ssquf] Last lane, IB AcK panel, and lanes 3 and 5, IB HSP90 panel,
are duplicated with resizing
[ssquf] Lane 4, IB AcK panel, and lanes 1, 4, and 6, IB HSP90
panel, are duplicated with resizing
[ssquf] Lane 4, IB AcK panel, is falsified and/or fabricated
<bullet> J Biol Chem. 2014:
--Figure 1D, representing expression of different proteins treated with
control or p53 siRNA:
[ssquf] Lane 1, p53 panel, and lanes 1 and 2, [beta]-actin panel,
are duplicated by reusing a same source band with manipulation
--Figure 2B, [beta]-actin panel, representing [beta]-actin expression
in HCT-15 cells treated with different doses of CP-31398:
[ssquf] Lane 1 and lane 5 are identical
[ssquf] Lane 2 and lane 6 are identical
--Figure 4K, p23 panel, representing p23 expression in samples treated
[[Page 62806]]
with different doses of CP-31398 in HCT-15 cells:
[ssquf] Lanes 2-4 are identical
--Figures 4H, 4I, and 4L, [beta]-actin panels, representing [beta]-
actin expression under different experimental conditions:
[ssquf] [beta]-actin panels in Figures 4H and 4I, and lanes 3-4,
[beta]-actin panel in Figure 4L are duplicated by reusing the same
source images with manipulation
--Figures 4J, 4K, and 4L, representing expression of HOP (Figure 4J)
and [beta]-actin (Figures 4K and 4L) under different experimental
conditions:
[ssquf] Lanes 1-2, HOP panel in Figure 4J, lanes 3-4, [beta]-actin
panel in Figure 4K, and lanes 1-2, [beta]-actin panel in Figure 4L are
duplicated by reusing the same source images with manipulation
--Figures 5A and 5B, [beta]-actin panels, representing [beta]-actin
expression in both HCT-15 cells and EB-1 cells, are identical
--Figure 5H, c-Myc panel and Naked-1 panel, representing expression of
c-Myc and Naked-1 in EB-1 cells, are duplicated with resizing
--Figures 10A and 10B, representing [beta]-actin (Figure 10A) and Aha1
(Figure 10B) expression:
[ssquf] Lanes 2-3, [beta]-actin panel in Figure 10A and lanes 2-3,
Aha1 panel in Figure 10B are duplicated with resizing
<bullet> J Biol Chem. 2016:
--Figures 1C and 7A, [beta]-actin panels, representing [beta]-actin
expression in different cells:
[ssquf] Lanes 1-2, [beta]-actin panel in Figure 1C and lanes 2-3,
[beta]-actin panel in Figure 7A are duplicated by reusing the same
source images with manipulation
--Figure 5B, representing expression of different proteins with
different treatments:
[ssquf] Lane 6, PKM2 panel, and lane 5, Hsp90 panel, are identical
--Figure 5A, representing expression of different proteins with
different treatments:
[ssquf] Lane 2, HIF-1[alpha] panel, and lane 1, [beta]-actin panel,
are identical
<bullet> Cancer Prev Res. 2008:
--Figure 2B, [beta]-actin panel, representing [beta]-actin expression
in different cells with different treatments:
[ssquf] Left middle [beta]-actin panel and right middle [beta]-
actin panel are duplicated by reusing the same source images with
manipulation
--Figures 3A and 3B, [beta]-actin panels, representing [beta]-actin
expression in different cells with different treatments:
[ssquf] Left top [beta]-actin panel in Figure 3A and left top
[beta]-actin panel in Figure 3B are identical
[ssquf] Right top [beta]-actin panel in Figure 3A and left bottom
[beta]-actin panel in Figure 3B are duplicated by reusing the same
source images with manipulation
[ssquf] Right bottom [beta]-actin panel in Figure 3A and right
bottom [beta]-actin panel in Figure 3B are identical
<bullet> Cancer Prev Res. 2011:
--Figure 3A, representing expression of different proteins with
different treatments:
[ssquf] Lane 1, aP2 panel, is falsified and/or fabricated
[ssquf] Lanes 3 and 5, aP2 panel, and lanes 1-6, 18S rRNA panel,
are identical
<bullet> Cancer Prev Res. 2012a:
--Figure 4A, representing input expression treated with different doses
of Zyflamend with or without 17-AAG:
[ssquf] Lanes 1-5 are identical
[ssquf] Lanes 6-7 are identical
--Figure 4B, representing input expression treated with different doses
of carnosol with or without 17-AAG:
[ssquf] Lanes 1-5 are identical
<bullet> Cancer Prev Res. 2012b:
--Figure 2, representing expression of different proteins under
different experimental conditions:
[ssquf] Lane 1, 15-PGDH panel in Figure 2B and lanes 3-4, [beta]-
Actin panel in Figure 2E are duplicated by reusing a same source band
with manipulation
[ssquf] Lane 2, [beta]-Actin panel in Figure 2B and lane 1, Snail
panel in Figure 2E are duplicated by reusing a same source band with
manipulation
[ssquf] Lane 3, Snail panel in Figure 2G and lane 1, 15-PGDH panel
in Figure 2H are duplicated by reusing a same source band with
manipulation
[ssquf] Lanes 1 and 2, [beta]-Actin panel in Figure 2H are
duplicated by reusing a same source band with manipulation
[ssquf] Lanes 1-3, [beta]-Actin panel in Figure 2J and lanes 1-2,
[beta]-Actin panel in Figure 2K are duplicated by reusing a same source
band with manipulation
--Figure 4E, [beta]-Actin panel, representing [beta]-actin expression
in control and pioglitazone samples:
[ssquf] Lanes 1 and 2 are identical
<bullet> Cancer Prev Res. 2013:
--Figure 3, representing binding of nuclear protein from mammary glands
of mice with different treatments:
[ssquf] Lanes 7-9 (first three empty lanes are counted also) and
lanes 13-15 are identical
<bullet> Cancer Prev Res. 2014:
--Figures 5A and 5C, representing expression of different proteins with
different treatments:
[ssquf] Lanes 2-3, CYP1A1 panel, and lanes 2-3, CYP1B1 panel, in
Figure 5A and lane 3, CYP1B1 panel, in Figure 5C are duplicated by
reusing a same source band with manipulation
--Figure 5B, [beta]-actin panel, representing [beta]-actin expression
in different cells with different treatments:
[ssquf] Lanes 2-4 are identical
--Figure 5D, [beta]-actin panel, representing [beta]-actin expression
in different cells with different treatments:
[ssquf] Lanes 1-4 are duplicated by reusing a same source band with
manipulation
<bullet> Cancer Prev Res. 2015:
--Figure 3A, [beta]-actin panel, representing [beta]-actin expression
in DLD-1 treated with different doses of PGE<INF>2</INF>:
[ssquf] Lanes 1, 3, and 5 are identical
[ssquf] Lanes 2 and 4 are identical
Respondent entered into a Voluntary Settlement Agreement
(Agreement) and voluntarily agreed to the following:
(1) Respondent will have his research supervised for a period of
seven (7) years beginning on August 14, 2023 (the ``Supervision
Period''). Prior to the submission of an application for PHS support
for a research project on which Respondent's participation is proposed
and prior to Respondent's participation in any capacity in PHS-
supported research, Respondent will submit a plan for supervision of
Respondent's duties to ORI for approval. The supervision plan must be
designed to ensure the integrity of Respondent's research. Respondent
will not participate in any PHS-supported research until such a
supervision plan is approved by ORI. Respondent will comply with the
agreed-upon supervision plan.
(2) The requirements for Respondent's supervision plan are as
follows:
i. A committee of 2 senior faculty members at the institution who
are familiar with Respondent's field of research, but not including
Respondent's supervisor or collaborators, will provide oversight and
guidance for a period of seven (7) years from the effective date of the
Agreement. The committee will review primary data from Respondent's
laboratory on a quarterly basis and submit a report to ORI at six (6)
month intervals setting forth the committee meeting dates and
Respondent's compliance with appropriate research standards and
confirming the integrity of Respondent's research.
ii. The committee will conduct an advance review of each
application for
[[Page 62807]]
PHS funds, or report, manuscript, or abstract involving PHS-supported
research in which Respondent is involved. The review will include a
discussion with Respondent of the primary data represented in those
documents and will include a certification to ORI that the data
presented in the proposed application, report, manuscript, or abstract
are supported by the research record.
(3) During the Supervision Period, Respondent will ensure that any
institution employing him submits, in conjunction with each application
for PHS funds, or report, manuscript, or abstract involving PHS-
supported research in which Respondent is involved, a certification to
ORI that the data provided by Respondent are based on actual
experiments or are otherwise legitimately derived and that the data,
procedures, and methodology are accurately reported and not plagiarized
in the application, report, manuscript, or abstract.
(4) If no supervision plan is provided to ORI, Respondent will
provide certification to ORI at the conclusion of the Supervision
Period that his participation was not proposed on a research project
for which an application for PHS support was submitted and that he has
not participated in any capacity in PHS-supported research.
(5) During the Supervision Period, Respondent will exclude himself
voluntarily from serving in any advisory or consultant capacity to PHS
including, but not limited to, service on any PHS advisory committee,
board, and/or peer review committee.
Dated: September 8, 2023.
Sheila Garrity,
Director, Office of Research Integrity, Office of the Assistant
Secretary for Health.
[FR Doc. 2023-19779 Filed 9-12-23; 8:45 am]
BILLING CODE 4150-31-P
</pre></body>
</html>Indexed from Federal Register on September 13, 2023.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.